Jump to Main Content
- Qin Lingyun, et al. Show all 7 Authors
- Biochemistry 2017 v.56 no.25 pp. 3273-3282
- amino acids; antineoplastic activity; drugs; fluorescence; fluorescence emission spectroscopy; ligands; models; neoplasms; oncogene proteins; screening; therapeutics
- ... In nearly half of cancers, the anticancer activity of p53 protein is often impaired by the overexpressed oncoprotein Mdm2 and its homologue, MdmX, demanding efficient therapeutics to disrupt the aberrant p53–MdmX/Mdm2 interactions to restore the p53 activity. While many potent Mdm2-specific inhibitors have already undergone clinical investigations, searching for MdmX-specific inhibitors has become ...
- Qin Lingyun, et al. Show all 6 Authors
- Journal of the American Chemical Society 2014 v.136 no.52 pp. 18023-18033
- antagonists; apoptosis; drugs; humans; models; neoplasm cells; neoplasms
- ... The aberrant interaction between p53 and Mdm2/MdmX is an attractive target for cancer drug discovery because the overexpression of Mdm2 and/or MdmX ultimately impairs the function of p53 in approximately half of all human cancers. Recent studies have shown that inhibition of both Mdm2 and MdmX is more efficient than that of a single target in promoting cellular apoptosis in cancers. In this study, ...